Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19

Mousavizadeh, 2021, Genotype and phenotype of COVID-19: Their roles in pathogenesis, J. Microbiol. Immunol. Infect., 54, 159, 10.1016/j.jmii.2020.03.022

Wu, 2020, Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China, Cell Host Microbe, 27, 325, 10.1016/j.chom.2020.02.001

Dhakal, 2021, Genes of SARS-CoV-2 and emerging variants, Microbiol. Aust., 42, 10, 10.1071/MA21004

Aleem, A., Akbar, A.B., and Slenker, A.K. (2021). Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). StatPearls, StatPearls Publishing.

Robishaw, 2021, Genomic surveillance to combat COVID-19: Challenges and opportunities, Lancet Microbe, 2, e481, 10.1016/S2666-5247(21)00121-X

Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., and Panda, S. (2021). SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms, 9.

Yang, 2021, COVID-19 pandemic dynamics in India and impact of the SARS-CoV-2 Delta (B.1.617.2) variant, medrxiv, 10, 11

Kimura, I., Kosugi, Y., Wu, J., Yamasoba, D., Butlertanaka, E.P., Tanaka, Y.L., Liu, Y., Shirakawa, K., Kazuma, Y., and Nomura, R.J.b. (2021). SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv, 10.

Naqvi, 2020, Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach, Biochim. Biophys. Acta Mol. Basis Dis., 1866, 256, 10.1016/j.bbadis.2020.165878

Wang, 2020, The genetic sequence, origin, and diagnosis of SARS-CoV-2, Eur. J. Clin. Microbiol. Infect. Dis., 39, 1629, 10.1007/s10096-020-03899-4

Sahin, 2021, Genomic characterization of SARS-CoV-2 isolates from patients in Turkey reveals the presence of novel mutations in spike and nsp12 proteins, J. Med. Virol., 93, 6016, 10.1002/jmv.27188

Cannalire, R., Cerchia, C., Beccari, A.R., Di Leva, F.S., and Summa, V. (2020). Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. J. Med. Chem.

Rut, 2021, SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging, Nat. Chem. Biol., 17, 222, 10.1038/s41589-020-00689-z

Yadav, R., Chaudhary, J.K., Jain, N., Chaudhary, P.K., Khanra, S., Dhamija, P., Sharma, A., Kumar, A., and Handu, S. (2021). Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells, 10.

Mendes, 2020, Role of nonstructural proteins in the pathogenesis of SARS-CoV-2, J. Med. Virol., 92, 1427, 10.1002/jmv.25858

2021, Structure of Nonstructural Protein 1 from SARS-CoV-2, J. Virol., 95, e02019

Yoshimoto, 2020, The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19, Protein J., 39, 198, 10.1007/s10930-020-09901-4

Shang, 2021, Compositional diversity and evolutionary pattern of coronavirus accessory proteins, Brief. Bioinform., 22, 1267, 10.1093/bib/bbaa262

Redondo, 2021, SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns, Front. Immunol., 12, 708264, 10.3389/fimmu.2021.708264

Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8

Zhang, 2021, Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy, Signal Transduct. Target. Ther., 6, 233, 10.1038/s41392-021-00653-w

Wu, 2020, Furin: A Potential Therapeutic Target for COVID-19, iScience, 23, 16, 10.1016/j.isci.2020.101642

Huang, 2020, Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19, Acta Pharmacol. Sin., 41, 1141, 10.1038/s41401-020-0485-4

Ke, 2020, Structures and distributions of SARS-CoV-2 spike proteins on intact virions, Nature, 588, 498, 10.1038/s41586-020-2665-2

Chatterjee, S.K., and Saha, S. (2021). Glycan and Its Role in Combating COVID-19. Biotechnology to Combat COVID-19, Intech Open.

Ahmed, S.F., Quadeer, A.A., and McKay, M.R. (2020). Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12.

Li, 2016, Structure, Function, and Evolution of Coronavirus Spike Proteins, Annu. Rev. Virol., 3, 237, 10.1146/annurev-virology-110615-042301

Weissman, 2021, D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization, Cell Host Microbe, 29, 23, 10.1016/j.chom.2020.11.012

Xia, 2019, A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike, Sci. Adv., 5, 4580, 10.1126/sciadv.aav4580

Tian, 2021, Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2, bioRxiv, 7, 19

Xia, 2020, The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin, Signal Transduct. Target. Ther., 5, 92, 10.1038/s41392-020-0184-0

Kok, 2020, The SARS-CoV-2 ‘perfect storm’.From humble betacoronavirus to global pandemic. From humble betacoronavirus to global pandemic, Microbiol. Aust., 41, 150, 10.1071/MA20040

Wang, 2020, A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility, Virol. Sin., 35, 337, 10.1007/s12250-020-00212-7

Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052

Escalera, 2021, SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage, bioRxiv, 8, 15

Zhang, 2020, SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, J. Hematol. Oncol., 13, 120, 10.1186/s13045-020-00954-7

Ord, 2020, The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV, Sci. Rep., 10, 16944, 10.1038/s41598-020-74101-0

Peacock, 2021, The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets, Nat. Microbiol., 6, 899, 10.1038/s41564-021-00908-w

Coutard, 2020, The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antivir. Res., 176, 104742, 10.1016/j.antiviral.2020.104742

Ganesan, 2020, Increased mortality of COVID-19 infected diabetes patients. Role of furin proteases, Int. J. Obes. (Lond.), 44, 2486, 10.1038/s41366-020-00670-9

McFadyen, 2020, The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications, Circ. Res., 127, 571, 10.1161/CIRCRESAHA.120.317447

Prompetchara, E., Ketloy, C., Tharakhet, K., Kaewpang, P., Buranapraditkun, S., Techawiwattanaboon, T., Sathean-anan-kun, S., Pitakpolrat, P., Watcharaplueksadee, S., and Phumiamorn, S. (2021). DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS ONE, 16.

Mohammadi, 2021, The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines, Braz. J. Infect. Dis., 25, 101606, 10.1016/j.bjid.2021.101606

Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., and Singh, S. (2021). SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. Nat. Portf.

Liu, Y., Liu, J., Johnson, B.A., Xia, H., Ku, Z., Schindewolf, C., Widen, S.G., An, Z., Weaver, S.C., and Menachery, V.D. (2021). Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv.

Vu, M.N., and Menachery, V.D. (2021). Binding and Entering: COVID Finds a New Home. PLOS Pathog., 17.

Padilla-Rojas, C., Jimenez-Vasquez, V., Hurtado, V., Mestanza, O., Molina, I.S., Barcena, L., Morales Ruiz, S., Acedo, S., Lizarraga, W., and Bailon, H. (2021). Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-CoV-2 lineage in Peru despite circulation of variants of concern. J. Med. Virol.

Planas, 2021, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature, 596, 276, 10.1038/s41586-021-03777-9

Yan, 2021, Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2, Cell Res., 31, 717, 10.1038/s41422-021-00490-0

Pettersen, 2021, Ferrin TEUCSF ChimeraX: Structure visualization for researchers, educators, and developers, Protein Sci., 30, 70, 10.1002/pro.3943

Shang, 2020, Structural basis of receptor recognition by SARS-CoV-2, Nature, 581, 221, 10.1038/s41586-020-2179-y

Lam, 2021, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell, 184, 2372, 10.1016/j.cell.2021.03.013

Hristova, 2011, A look at arginine in membranes, J. Membr. Biol., 239, 49, 10.1007/s00232-010-9323-9

Rees, 2021, Altered amino acid profile in patients with SARS-CoV-2 infection, Proc. Natl. Acad. Sci. USA, 118, e2101708118, 10.1073/pnas.2101708118

Plante, 2021, The variant gambit: COVID-19′s next move, Cell Host Microbe, 29, 508, 10.1016/j.chom.2021.02.020

Kannan, 2021, Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses, J. Autoimmun., 124, 102715, 10.1016/j.jaut.2021.102715

Starr, 2021, Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016, Cell Rep. Med., 2, 100255, 10.1016/j.xcrm.2021.100255

Rezaei, S., Sefidbakht, Y., and Uskoković, V. (2020). Comparative molecular dynamics study of the receptor-binding domains in SARS-CoV-2 and SARS-CoV and the effects of mutations on the binding affinity. J. Biomol. Struct. Dyn., 1–20.

Bian, L., Gao, Q., Gao, F., Wang, Q., He, Q., Wu, X., Mao, Q., Xu, M., and Liang, Z. (2021). Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev. Vaccines, 1–9.

Acevedo, 2021, Valiente-Echeverria F, Soto-Rifo R: Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda, Medrxiv, 8, 15

Snell, 2021, SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: A review, Am. J. Emerg. Med., 40, 188, 10.1016/j.ajem.2020.09.072

Issa, 2020, SARS-CoV-2 and ORF3a: Nonsynonymous mutations, functional domains, and viral pathogenesis, Msystems, 5, e00266-20, 10.1128/mSystems.00266-20

Banoun, 2021, Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System, Nephron, 145, 392, 10.1159/000515417

Ho, F.K., Petermann-Rocha, F., Gray, S.R., Jani, B.D., Katikireddi, S.V., Niedzwiedz, C.L., Foster, H., Hastie, C.E., Mackay, D.F., and MGill, J.M.R. (2020). Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS ONE, 15.

Bakhshandeh, 2021, Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus, Microb. Pathog., 154, 104831, 10.1016/j.micpath.2021.104831

Wang, 2020, The establishment of reference sequence for SARS-CoV-2 and variation analysis, J. Med. Virol., 92, 667, 10.1002/jmv.25762

Cagliani, 2020, Genetics, Evolution. Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses, Infect. Genet. Evol., 83, 104353, 10.1016/j.meegid.2020.104353

Dhakal, 2021, Could the severity of COVID-19 be enhanced by ORF10 accessory proteins?, Curr. Top. Pept. Protein Res., 21, 97

Kwarteng, 2020, Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques, Biomed. Pharmacother., 132, 110914, 10.1016/j.biopha.2020.110914

Salvatori, 2020, SARS-CoV-2 spike protein: An optimal immunological target for vaccines, J. Transl. Med., 18, 222, 10.1186/s12967-020-02392-y

Foss, 2019, TRIM21—From Intracellular Immunity to Therapy, Front. Immunol., 10, 2049, 10.3389/fimmu.2019.02049

Johnson, B.A., Xie, X., Kalveram, B., Lokugamage, K.G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J.K., and Zhang, L. (2020). Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. bioRxiv.